Association of a very high tumor mutational load with increased CD8+and PD-1+T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.

被引：2

作者：

Ricciuti, Biagio

Arbour, Kathryn Cecilia

Alessi, Joao Victor Machado

Mahadevan, Navin

Lindsay, James

Sinha, Rileen

Vokes, Natalie I.

Recondo, Gonzalo

Lamberti, Giuseppe

Rizvi, Hira

Leonardi, Giulia Costanza

Plodkowski, Andrew J.

Felt, Kristen

Tolstorukov, Michael

Janne, Pasi A.

Van Allen, Eliezer Mendel

Sholl, Lynette M.

Rodig, Scott J.

Hellmann, Matthew D.

Awad, Mark M.

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Dana Farber Canc Inst, Knowledge Syst Grp, Boston, MA 02115 USA

[5] Dana Farber Canc Inst, Dept Informat & Analyt, Boston, MA 02115 USA

[6] Dana Farber Canc Inst, ImmunoProfile, Boston, MA 02115 USA

[7] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA

[8] Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA

[9] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9018

引用

页数：4

共 50 条

[31] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
Kerr, Keith M.
Nicolson, Marianne C.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
[32] Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
Huang, Mu-Yang
Jiang, Xiao-Ming
Wang, Bing-Lin
Sun, Yang
Lu, Jin-Jian
PHARMACOLOGY & THERAPEUTICS, 2021, 219
[33] Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Li, Lijun
Pu, Haihong
Zhang, Xiaoxin
Guo, Xiaotian
Li, Guangrui
Zhang, Minghui
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
[34] Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
Nojima, Yuji
Shimizu, Katsuhiko
Saisho, Shinsuke
Maeda, Ai
Kurosaki, Takeshi
Kurose, Koji
Oga, Toru
Oka, Mikio
Nakata, Masao
ANTICANCER RESEARCH, 2021, 41 (11) : 5469 - 5475
[35] A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non-Small Cell Lung Cancer
Man, J.
Gebski, V.
Mulvey, A.
Hui, R.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2001 - S2002
[36] PD-L1 Expression in Small Cell Lung Cancer
Yasuda, Yuto
Ozasa, Hiroaki
Kim, Young Hak
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : E40 - E41
[37] PD-L1 expression in small cell lung cancer
Komiya, Takefumi
Madan, Rashna
EUROPEAN JOURNAL OF CANCER, 2015, 51 (13) : 1853 - 1855
[38] BATF2 inhibits PD-L1 expression and regulates CD8+T-cell infiltration in non-small cell lung cancer
Liu, Junwei
Li, Jie
Tuo, Zhan
Hu, Weidong
Liu, Jun
JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (11)
[39] A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.
Ricciuti, Biagio
Arbour, Kathryn C.
Mahadevan, Navin R.
Alessi, Joao V.
Lindsay, James
Umeton, Renato
Sinha, Rileen
Hoojghan, Amir
Vokes, Natalie
Recondo, Gonzalo
Lamberti, Giuseppe
Polio, Andrew
Rizvi, Hira
Leonardi, Giulia
Plodkowski, Andrew J.
Felt, Kristen
Sharma, Bijaya
Tolstorukov, Michael Y.
Janne, Pasi A.
Van Allen, Eliezer M.
Sholl, Lynette M.
Rodig, Scott J.
Hellmann, Matthew D.
Awad, Mark M.
CANCER RESEARCH, 2021, 81 (13)
[40] Discrepancies in PD-L1 expression, lymphocyte infiltration, and tumor mutational burden in non-small cell lung cancer and matched brain metastases
Zhang, Yanhui
Cheng, Runfen
Ding, Tingting
Wu, Jianghua
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12)

← 1 2 3 4 5 →